SIRION BIOTECH's investors believe in the benefits of viral platform technologies for the future availability of

  • most sophisticated in vitro cell models - for improved compound screening in the fields of drug discovery and the development of novel food and cosmetic additives
  • serotype adenovirus vectors for novel vaccines - formuch improved prime boost characteristics
  • viral vectors for novel gene therapy

 

 

Benefits to the Clients are multifold:

  • most importantly, development cycles can be reduced by 20-60%!
  • In addition, research with well developed cell lines provides results that are significantly more precise: accordingly,
    • gene knockdowns of nearly 100% are now in sight, much improved over the current industry standard of 50%
    • 3D models come significantly closer to 'real' cells
  • Customized Primary Cells immortalized are now in reach - SIRION BIOTECH has successfully immortalized a number of these
  • Only extensive experience with viral vector technologies allows for serotype vector construction, another skill patented by SIRION BIOTECH.